An alumni of JLab San Francisco, Alector LLC (NASDAQ:ALEC) is a biotechnology company developing antibody therapeutics for Alzheimers disease, other forms of dementia, and mechanistically related neurodegenerative disorders. The company combines antibody technology with neuroimmunology and human genetics to develop their novel therapeutics, generating antibody drugs with unique functional properties that engage key disease-altering targets. The firm has a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is also developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams. Alector completed its IPO in February 2019 raisng an amount in the mid-range of what had been anticipated.
